Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized …
B Han, B Jin, T Chu, Y Niu, Y Dong, J Xu… - … journal of cancer, 2017 - Wiley Online Library
To explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations,
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for …
A Inoue, K Yoshida, S Morita, F Imamura… - Japanese journal of …, 2016 - academic.oup.com
Abstract Background The Japan Guidelines of Lung Cancer Therapy recommend epidermal
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus …
Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases
HS Han, DW Eom, JH Kim, KH Kim, HM Shin, JY An… - Clinical lung cancer, 2011 - Elsevier
Introduction The aim of this study was to compare epidermal growth factor receptor (EGFR)
and KRAS mutations between primary tumors and corresponding metastases including …
and KRAS mutations between primary tumors and corresponding metastases including …
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
Purpose: Patients with epidermal growth factor receptor (EGFR)-mutant lung
adenocarcinoma develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI) after …
adenocarcinoma develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI) after …
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma …
This study was designed to prospectively evaluate the efficacy and safety of first-line gefitinib
treatment in patients with advanced pulmonary adenocarcinoma harboring epidermal …
treatment in patients with advanced pulmonary adenocarcinoma harboring epidermal …
[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations
CH Chiu, CT Yang, JY Shih, MS Huang, WC Su… - Journal of thoracic …, 2015 - Elsevier
Background Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
[HTML][HTML] A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology …
Y Shi, JSK Au, S Thongprasert, S Srinivasan… - Journal of thoracic …, 2014 - Elsevier
Introduction: PIONEER (NCT01185314) was a prospective, multinational, epidemiological
study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly …
study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly …
[HTML][HTML] Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs
JJ Lin, S Cardarella, CA Lydon, SE Dahlberg… - Journal of Thoracic …, 2016 - Elsevier
Introduction Activating mutations in the epidermal growth factor receptor gene (EGFR)
predict for prolonged progression-free survival in patients with advanced non–small cell …
predict for prolonged progression-free survival in patients with advanced non–small cell …
[HTML][HTML] Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene …
P Krawczyk, DM Kowalski, R Ramlau… - Oncology …, 2017 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …